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With limited therapeutic intervention in preventing the progression to end-stage renal 
disease, chronic kidney disease (CKD) remains a global health-care burden. Aristolochic 
acid (AA) induced nephropathy is a model of CKD characterised by inflammation, tubular 
injury, and interstitial fibrosis. Human liver stem cell-derived extracellular vesicles (HLSC-
EVs) have been reported to exhibit therapeutic properties in various disease models 
including acute kidney injury. In the present study, we aimed to investigate the effects 
of HLSC-EVs on tubular regeneration and interstitial fibrosis in an AA-induced mouse 
model of CKD. NSG mice were injected with HLSC-EVs 3  days after administering 
AA on a weekly basis for 4 weeks. Mice injected with AA significantly lost weight over 
the 4-week period. Deterioration in kidney function was also observed. Histology was 
performed to evaluate tubular necrosis, interstitial fibrosis, as well as infiltration of inflam-
matory cells/fibroblasts. Kidneys were also subjected to gene array analyses to evaluate 
regulation of microRNAs (miRNAs) and pro-fibrotic genes. The effect of HLSC-EVs was 
also tested in vitro to assess pro-fibrotic gene regulation in fibroblasts cocultured with 
AA pretreated tubular epithelial cells. Histological analyses showed that treatment with 
HLSC-EVs significantly reduced tubular necrosis, interstitial fibrosis, infiltration of CD45 
cells and fibroblasts, which were all elevated during AA induced injury. At a molecular 
level, HLSC-EVs significantly inhibited the upregulation of the pro-fibrotic genes α-Sma, 
Tgfb1, and Col1a1 in vivo and in vitro. Fibrosis gene array analyses revealed an upreg-
ulation of 35 pro-fibrotic genes in AA injured mice. Treatment with HLSC-EVs downreg-
ulated 14 pro-fibrotic genes in total, out of which, 5 were upregulated in mice injured 
with AA. Analyses of the total mouse miRnome identified several miRNAs involved in 
the regulation of fibrotic pathways, which were found to be modulated post-treatment 
with HLSC-EVs. These results indicate that HLSC-EVs play a regenerative role in CKD 
possibly through the regulation of genes and miRNAs that are activated during the 
progression of the disease.
Keywords: aristolochic acid nephropathy, extracellular vesicles, human liver stem cells, chronic kidney disease, 
mirna, fibrosis
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inTrODUcTiOn
Chronic kidney disease (CKD) is a pathology that affects billions 
of individuals globally (1). Currently, treatment for end-stage 
CKD is limited to haemodialysis and kidney transplantation, both 
of which are restricted to financial restraint and/or availability 
of donor kidneys (2). Interstitial fibrosis, a hallmark of CKD is 
now accepted as an independent contributor/predictor of disease 
progression, therefore, making it a potential target for therapy (3). 
Fibrosis is mainly characterised by the release of inflammatory 
mediators, infiltration of inflammatory/immune cells, activation 
and proliferation of resident fibroblasts, epithelial to mesenchy-
mal transition (EMT), and dysregulation of extracellular matrix 
(ECM) deposition (4). Aristolochic acid nephropathy (AAN) is a 
rapidly progressing form of kidney disease that occurs in patients 
who have ingested plants containing aristolochic acid (AA) as part 
of traditional herbal therapy (Chinese herb nephropathy) or as a 
food contaminant (Balkan endemic nephropathy) (5). AAN is 
predominantly characterised by interstitial fibrosis accompanied 
with tubular atrophy and EMT that eventually progresses towards 
end-stage renal disease (5). There is also a potential of developing 
urothelial malignancies due to DNA adducting properties of AA 
(5). Although, various pathways have been implicated in kidney 
fibrosis, the transforming growth factor beta (TGFβ) signalling 
pathway remains to be a major contributor (4).
Stem cell-based therapies have gathered a substantial amount 
of interest over the past decade. They have been implicated as 
potential treatments in various disease conditions including 
acute and chronic renal injury. For instance, mesenchymal 
stem cells (MSC) were shown to exhibit a protective role in an 
animal model of obstruction-induced renal fibrosis by reducing 
the activation of signal transducer and activator of transcrip-
tion 3 (6). Furthermore, human amniotic fluid derived-stem 
cells played a protective role by alleviating interstitial fibrosis 
in a mouse model of unilateral ureter obstruction (2). Human 
liver stem cells (HLSCs), a stem cell population resident in the 
liver, discovered in our lab (7), also exhibit mesenchymal and 
embryonic markers together with a multipotency potential to 
differentiate into several types of cells (7). Over the years, we have 
found these cells to display remarkable therapeutic properties. 
In a model of acetaminophen-induced liver injury, HLSCs proved 
to contribute towards the regeneration of liver parenchyma (7). 
Whereas, in a model of fulminant liver failure, mouse survival 
rate was increased after treatment with HLSCs (8). Nonetheless, 
the regenerative potential of HLSCs is not limited to the liver 
only. In a model of acute kidney injury (AKI), mice treated 
with HLSCs showed improved renal morphology and function 
substantially (9).
The mechanism through which stem cells exert their biologi-
cal effect has been suggested to be of paracrine in nature. Factors 
released by stem cells, either directly or through packaged 
vesicles, interact with recipient cells and exert therapeutic effects 
(10). In fact, the mechanism and function through which cells 
package and transfer biologically active molecules in the form of 
extracellular vesicles (EVs) has gained huge interest over the last 
few years (10). EVs are heterogeneous lipid membrane vesicles 
released by cells either through membrane shedding or fusion of 
multivesicular bodies with the cell membrane (11). They tend to 
influence target cells by delivering biologically active cargo such 
as: proteins, lipids, and nucleic acids (11).
Therapeutic effects exhibited by stem cell-derived EVs are very 
well documented in the scientific literature. For instance, Bruno 
et  al. (12) showed that MSC-derived EVs not only increased 
survival but also promoted overall healing and proliferation of 
tubular epithelial cells in a mouse model of AKI. In a model of 
renal ischaemia/reperfusion, MSC-derived EVs reduced injury 
and augmented renal recovery compared to untreated mice (13). 
HLSC-derived EVs, like MSC-EVs, have also been functionally 
and molecularly characterised (14). In addition, like their cellular 
counterpart, human liver stem cell-derived extracellular vesicles 
(HLSC-EVs) also exhibit regenerative properties in various 
models of tissue pathology including AKI (9, 15).
The therapeutic potential of EVs derived from HLSCs in CKD 
and, in particular, AAN has yet to be elucidated. The aim of this 
study was, therefore, to investigate whether EVs from HLSCs 
contribute towards tubular regeneration and alleviate fibrosis in 
a chronic mouse model of AAN.
MaTerials anD MeThODs
isolation and characterisation of eVs
Extracellular vesicles were obtained from supernatants of 
HLSCs (2 × 106 cells/T75 flask) or MRC5 human dermal fibro-
blasts cultured in serum-free Roswell Park Memorial Institute 
Medium (RPMI) (Euroclone S.p.A, Italy) for 18 h. Viability of 
cells at the time of supernatant collection was 98% as confirmed 
by Trypan blue exclusion. Briefly, supernatants were centrifuged 
at 3,000 g for 15 min at 4°C for the removal of cell debris and 
apoptotic bodies, followed by ultracentrifugation at 100,000 g 
for 2 h at 4°C (Beckman Coulter Optima L-90 K, Fullerton, CA, 
USA). The pellet of EVs obtained was resuspended in RPMI 
supplemented with 1% dimethyl sulfoxide (DMSO) and stored 
at −80°C until use. Further purification of EVs was performed 
by iodixanol (Optiprep, Sigma, St. Louis, MO, USA) floating 
density separation protocol as described previously (16). The 
protocol was modified from the initial one described by Kowal 
et  al. (17) to accommodate for larger centrifugation volumes 
to obtain sufficient amounts of EVs for in  vivo experiments. 
Briefly, EVs acquired through ultracentrifugation were 
resuspended in 500  µl of 60% iodixanol supplemented with 
0.25 M sucrose. One ml of 30, 15, and 5% iodixanol working 
solution was layered sequentially above the EV/60% iodixanol 
suspension and the final volume adjusted to 10 ml with saline 
solution. The tubes were ultracentrifuged at 350,000 g for 1 h 
at 4°C without brake in an Optima L-100K ultracentrifuge 
Abbreviations: CKD, chronic kidney disease; AA, aristolochic acid; AAN, 
aristolochic acid nephropathy; HLSC, human liver stem cell; TGFb, transform-
ing growth factor beta; α-Sma, alpha smooth muscle actin; LTBP1, latent TGFb 
binding protein 1; EMT, epithelial to mesenchymal transition; ECM, extracellular 
matrix; AKI, acute kidney injury; DMSO, dimethyl sulfoxide; α-MEM, alpha mini-
mum essential medium; EBM, endothelial basal medium; mTEC, mouse tubular 
epithelial cell; mkCF, mouse kidney cortical fibroblast; WNT, wingless-related 
integration site; PDGF, platelet-derived growth factor; EGF, epidermal growth 
factor; FGF, fibroblast growth factor.
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(Beckman Coulter) equipped with Type 90Ti rotor. The 15, 
30, and 60% fractions were recovered, diluted in PBS and re-
ultracentrifuged at 100,000 g for 1 h at 4°C. The pellet obtained 
was resuspended in PBS/1% DMSO for subsequent studies. EVs 
were mainly detected in the 15% fraction as determined by the 
Nanosight LM10 system (NanoSight, Wiltshire, UK) (Figure 
S1A in Supplementary Material). EVs isolated from the 15% 
fraction were used for experiments.
Characterisation of EVs was performed by cytofluorimetric 
analyses. HLSC-EVs were positive for the typical mesenchymal 
surface markers characteristic of HLSCs such as CD29, CD44, 
CD73, and CD90 as well as the exosomal markers CD81 and 
CD107 as described before (9). A further characterisation was 
performed by electron microscopy showing the presence of 
vesicles ranging between 40 and 100  nm (15) (Figure S1B in 
Supplementary Material). Western blot analyses of EV protein 
also confirmed the presence of classical exosomal markers such 
as CD63, CD81, and TSG101 as described previously (9) (Figure 
S1C in Supplementary Material).
For EV internalisation experiments, EVs were labelled with 
1  µM Dil dye (Thermo Fisher Scientific, Waltham, MA, USA) 
as described before (15). Briefly, purified EVs were resuspended 
in PBS together with 1 µM Dil dye and ultracentrifuged for 1 h 
at 4°C. The pellet of EVs obtained was washed once by ultra-
centrifugation and resuspended in PBS/1% DMSO for use in 
experiments.
Quantification and size distribution of purified EVs was 
determined by Nanosight (NanoSight, Wiltshire, UK). Briefly, EV 
preparations were diluted (1:200) in sterile saline solution and 
analysed by the Nanoparticle Analyses System using the NTA 1.4 
Analytical Software as described previously (9).
cell culture
Human Liver Stem Cell
Human liver stem cells were isolated from human cryopreserved 
normal adult hepatocytes (Lonza, Basel, Switzerland) as described 
before (9). Briefly, hepatocytes were cultured in Hepatozyme-SFM 
medium (Lonza, Basel, Switzerland) for 2 weeks to allow majority 
of the hepatocytes to die. The surviving population of cells were 
cultured in alpha minimum essential medium/endothelial basal 
medium-1 (3:1) (Lonza, Basel, Switzerland) supplemented with 
l-glutamine (5 mM), HEPES (12 mM, pH 7.4), penicillin (50 IU/
ml), streptomycin (50  µg/ml) (all from Sigma, St. Louis, MO, 
USA), and 10% fetal calf serum (FCS) (Invitrogen, Carlsbad, CA, 
USA). Cells were expanded, characterised, and cryo-preserved as 
described previously (9).
Human liver stem cells were positive for the mesenchymal 
stem cell markers, but not haematopoietic and endothelial mark-
ers as described before (9). In addition, they were positive for 
human albumin, alpha-fetoprotein, resident stem cell markers 
such as vimentin and nestin, and negative for CD34, CD117, 
and cytokeratin 19 oval cell markers as reported previously (9). 
Embryonic stem cell markers such as Nanog, Oct4, Sox2, and 
SSEA4 were also positively expressed in HLSCs (9). Stemness of 
HLSCs was confirmed by endothelial, osteogenic, and hepatic 
differentiation under appropriate culture conditions as described 
earlier (9).
MRC5 Human Lung Fibroblasts
The human fetal lung fibroblast like cell line MRC5 PD 19 
(purchased from Sigma, St. Louis, MO, USA) was adopted for 
the isolation of EVs as a negative control for in vivo studies. 
Briefly, cells were cultured in Dulbecco’s modified essential 
medium (DMEM) low glucose supplemented with l-glutamine 
(5  mM), HEPES (12  mM, pH 7.4), penicillin (50  IU/ml), 
streptomycin (50  µg/ml), and 10% FCS. At a confluency of 
90%, cells were starved overnight in serum-free RPMI. The 
supernatant was collected and subjected to EV isolation as 
mentioned above.
Mouse Tubular Epithelial Cells (mTEC)
Mouse tubular epithelial cells isolated from kidneys of healthy 
female C57 mice [as described previously in our lab (12)] were 
cultured in DMEM supplemented with l-glutamine (5  mM), 
penicillin (50 IU/ml), streptomycin (50 µg/ml), and 10% FCS.
Mouse Kidney Cortical Fibroblasts (mkCF)
Mouse kidney cortical fibroblasts were isolated from the kidneys 
of healthy male CD1 mice using a modified protocol described by 
Grimwood and Masterson (18). Briefly, cortical sections of kid-
neys from CD1 mice were minced and plated on gelatin-coated 
petridishes and incubated at 37°C for 72 h in DMEM high glucose 
supplemented with l-glutamine (5 mM), penicillin (50 IU/ml), 
streptomycin (50  µg/ml), 10  ml HEPES, and 20% FCS. The 
medium was replaced after 72 h and cultures allowed to grow for 
10–14 days until a 75% confluent monolayer of fibroblast like cells 
was formed. Cells were further expanded and characterised for 
fibroblast lineage. Media was changed twice weekly to maintain 
cultures.
Fibroblasts were characterised through a series of inclusion/
exclusion criteria according to their distinctive biochemical 
and morphological characteristics as reported previously (18). 
Cells were positive for established mesenchymal markers such 
as: vimentin and α-SMA, as well as fibroblast-specific protein 
1 (FSP1), a marker of fibroblasts (19). In addition, expression 
of the endothelial/epithelial cell marker pan-cytokeratin was 
found to be negative, together with minimal expression of 
desmin (smooth muscle cell marker), therefore, confirming no 
contamination from these cells (18) (Figure S2 in Supplementary 
Material).
internalization of hlsc-eVs
For EV internalisation experiments, 2.5 × 104 mkCF cells were 
seeded 24  h prior to treatment on gelatinised coverslips in a 
24-well plate. Cells were then incubated for 6 h at 37°C with Dil 
labelled HLSC-EVs at a ratio of 4,000 EVs/cell in 2% FCS/DMEM 
high glucose medium. Post incubation, cells were fixed with 4% 
paraformaldehyde (Sigma, St. Louis, MO, USA) for 15 min at 4°C 
and permeabilised with 0.1% Triton-X100/PBS for 5 min at 4°C. 
Fluorescein isothiocyanate (FITC)-conjugated phalloidin dye 
(Thermo Fisher Scientific) (1:500) was then applied to the cells 
in 0.1% BSA/PBS for 1 h at room temperature. Post incubation, 
cells were washed twice with PBS for 5 min. Nuclei were stained 
with DAPI nuclear dye (Thermo Fisher Scientific) (1:5,000) for 
FigUre 1 | Human liver stem cell-derived extracellular vesicles (HLSC-EVs) exhibit antifibrotic effects in aristolochic acid nephropathy (AAN) in vivo. (a) Schematic 
overview of the experimental design for AAN in vivo showing the day of administration of aristolochic acid (AA), HLSC-EVs, or Fibro-EVs (EV) for 4 weeks (Wk).  
(B) Mice body weight was measured weekly prior to AA injections for 4 weeks and just before sacrifice. The body weight is represented as percentage weight 
change. A two-way analyses of variance (ANOVA) was performed with Bonferroni’s multi comparison test; data show mean ± SEM of nine mice per group. 
***p < 0.001 AA vs control or Fibro-EVs vs control and #p < 0.05 HLSC-EVs vs AA. (c) Plasma creatinine levels were assessed in mice treated with vehicle alone  
or mice injected with AA or AA mice injected with HLSC-EVs or Fibro-EVs (n = 9 mice per group). ***p < 0.001 AA vs control and **p < 0.01 HLSC-EVs vs AA.  
Data show mean ± SEM; a one-way ANOVA with Bonferroni’s multi comparison test was performed.
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10 min. Cover-slips were mounted on to glass slides and stored at 
4°C until confocal microscopy.
aa In Vitro Model
In order to study the effects of HLSC-EVs on mkCFs, an in vitro 
model of AA-induced fibrosis was set up. Briefly, 1.5 × 104 mTECs 
pre-seeded in a 24-well cell culture inserts (1.0 µm pore) (Thermo 
Fisher Scientific) were exposed to 100 µM of AA for 4 h. Post 
incubation, cells were washed and cocultured with mkCF cells 
(2 × 104 cells pre-seeded 24 h prior to the coculture) for 5 days at 
37°C. For selected experiments, HLSC-EVs were added to fibro-
blasts cocultured with AA exposed mTECs at a concentration 
50,000 EVs/cell. After 5 days of incubation, mkCFs were analysed 
for fibrotic gene expression by qRT-PCR. Fibroblasts cocultured 
with healthy mTECs served as controls.
aan In Vivo Model
Animal studies were conducted in accordance with the National 
Institute of Health Guidelines for the Care and Use of Laboratory 
Animals. All procedures were approved by the Ethics Committee 
of the University of Turin and the Italian Health Ministry (authori-
sation number: 766/2016-PR). AAN was induced by injecting 
male NOD/SCID/IL2Rγ KO (NSG) mice (bred at the animal 
facility in the Molecular Biotechnology Centre) (6/8 weeks old; 
n = 12) with 4 mg/kg of AA (Santa Cruz Biotechnology, Santa 
Cruz CA, USA) on a weekly basis for 4 weeks intraperitoneally 
(Figure 1A). HLSC-EVs (n = 9) or fibroblast-derived EVs (Fibro-
EVs; as negative control; n = 5) at a concentration of 1 × 1010 
EVs/ml/mouse or vehicle alone (n = 5; as control) were injected 
3 days after AA administration intravenously on a weekly basis 
(Figure 1A). After 4 weeks of treatments, mice were sacrificed 
and subjected to multi-parameter analyses as mentioned below. 
Five animals injected with PBS instead of AA served as controls. 
NSG immunodeficient mice were adopted for this study to pre-
vent an immunogenic reaction during repeated administration 
of EVs.
Plasma creatinine and Body Weight
Kidney function of mice exposed to AA in the presence or 
absence of HLSC-EVs or Fibro-EVs was assessed by measuring 
blood plasma creatinine after sacrifice. Plasma creatinine was 
measured using a colourimetric microplate assay based on the 
Jaffe reaction (Quantichrom Creatinine Assay, BioAssay systems, 
Hayward, CA, USA) as per manufacturer’s protocol. Body weight 
of mice was also measured as a parameter for general health 
weekly before administering AA and at the end of the experiment 
prior to sacrifice.
rna extraction and qrT-Pcr
Total RNA was isolated from cells using TRIzol™ (Ambion, 
Thermofisher) followed by RNA extraction using the miRNe-
asy mini kit (Qiagen, Venlo, The Netherlands) according to the 
TaBle 1 | List of primers used for qRT-PCR.
gene Primer sequence
m_Col1 Forward ATC TCC TGG TGC TGA TGG AC
m_Col1 Reverse ACC TTG TTT GCC AGG TTC AC
m_Tgfb1 Forward CGA AAG CCC TGT ATT CCG TCT
m_Tgfb1 Reverse GCA ACA ATT CCTGGC GTT ACC
m_α-Sma Forward CTG ACA GAG GCA CCA CTG AA
m_α-Sma Reverse CAT CTC CAG AGT CCA GCA CA
m_Ltbp1 Forward GGA GCC CGA AGT GGT AAC AG
m_Ltbp1 Reverse GAA TAG TTG AAA CCC CTG GGG
m_Gapdh Forward TGT CAA GCT CAT TTC CTG GTA TGA
m_Gapdh Reverse TCT TAC TCC TTG GAG GCC ATG T
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manufacturer’s protocol. Isolation of total RNA from mouse 
tissue was performed using the TRIzol™ as per manufacturer’s 
protocol. Briefly, mouse renal tissue was resuspended in 1 ml 
of TRIzol™ solution and homogenised in a Bullet blender 
(Next Advance Inc., New York, NY, USA) at a speed of 8 rpm 
for 3  min using 3.2  mm size zirconium pellets. Tubes were 
rotated on a rotator at 4°C for 30  min and centrifuged at 
12,000  g for 15  min at 4°C. Supernatant from homogenised 
tissue was transferred to clean tubes and subjected to RNA 
isolation as mentioned above. Total RNA from HLSC-EVs 
was extracted using the All-in-one purification kit (Norgen, 
Biotek Corp.) as per manufacturer’s protocol. Isolated RNA 
was quantified using the NanoDrop2000 spectrophotometer 
(Thermo Fisher Scientific) and either used immediately or 
stored at −80°C until further use. For the synthesis of cDNA, 
200 ng of RNA was retro-transcribed using the High Capacity 
cDNA reverse transcription kit (Applied Biosystems, Thermo 
Fisher Scientific) as per manufacturer’s protocol. qRT-PCR was 
performed using the StepOne Plus RT-PCR machine (Applied 
Biosystems) in 20  µl reaction mixtures containing: 4  ng of 
sample cDNA, specific oligonucleotide primers (Table  1) 
(MWG-Biotech, Eurofins Scientific, Brussels, Belgium) and 
Power SYBR Green PCR Master Mix (Applied Biosystems). 
Gapdh served as housekeeping gene. The data were analysed 
using ΔΔCt method.
renal histopathology
Renal histology was assessed by staining 5  µm-thick kidney 
sections with haematoxylin and eosin (H&E, Merck, Darmstadt, 
Germany) or Masson’s Trichrome stain and analysed through 
microscopic examination. Tubular necrosis was assessed in non-
overlapping fields (10/section) with an objective of 40× (high 
power field, HPF). Interstitial fibrosis was quantified by measur-
ing collagenous fibrotic areas stained in blue (sections stained 
with Masson’s trichrome) in 10 random cortical fields/section 
from images taken at a magnification of 20× using multiphase 
image analysis with ImageJ software version 1.49s (20).
Immunohistochemistry was performed as described previ-
ously (9). Briefly, 5  µm-thick kidney sections were subjected 
to antigen retrieval, blocking and labelling with monoclonal 
anti-proliferating cell nuclear antigen (PCNA) (Santa Cruz 
Biotechnology) at a concentration of 1:400. Secondary horse-
radish peroxide conjugated antibody (Pierce, Rockford, IL, 
USA) was applied and the slides analysed via microscopy. 
Histological scoring was performed by counting the number 
of positive nuclei per HPF (40×) in 10 random sections of the 
renal cortex.
Immunofluorescence was performed on 5 µm-thick cryostat 
sections. Briefly, sections were stained with mouse anti-CD45 
(Biorbyt, San Francisco CA, USA), mouse anti-S100A4 [fibroblast 
specific protein 1 (FSP-1)] (Abcam, Cambridge, MA, USA), or 
mouse anti-collagen 1 (Abcam) for 2 h at 4°C. This was followed 
by FITC or Texas red conjugated secondary antibody staining for 
1 h at room temperature. Sections were mounted and analysed via 
confocal microscopy. Sections labelled with secondary antibod-
ies only, served as controls. All the above image analyses were 
performed in a double blind format.
Fibrosis array and mirnome array
In order to elucidate the regulation of pro-fibrotic genes in mice 
treated with AA in the presence or absence of HLSC-EVs, total 
RNA extracted from kidneys of experimental mice were analysed 
using the Fibrosis RT2 Profiler PCR array (PAMM-120Z, Qiagen) 
as per manufacturer’s protocol. Analyses were performed using 
the online software provided by the manufacturer with global 
normalisation. A total of three mice per experimental group 
were subjected to array analyses. Furthermore, total RNA 
from the same mice was subjected to miRNA analyses using 
the QuantiMir™ mouse miRNome microRNA profiler array 
(RA670A-1, Systems Biosciences, Palo Alto, CA, USA) accord-
ing to manufacturer’s protocol. In addition, total RNA from 
mkCF from the in vitro experiments were subjected to miRNA 
analyses using the QuantiMir™ mouse miRNome microRNA 
profiler array. Only selected microRNAs (miRNAs) upregulated 
or downregulated by HLSC EVs following AA treatment in mice 
(in vivo) were assessed.
Bioinformatic analyses
Data obtained from the mouse miRnome array were subjected 
to bioinformatic analyses. Briefly, gene target prediction 
analyses and biological pathway analyses was performed using 
MirWalk v2.0 (21) and Panther gene ontology analyses tool 
(22) available online. Only biological processes of selected 
genes showing a p value < 0.05 were considered as significantly 
enriched.
electron Microscopy
Transmission electron microscopy was performed by loading 
HLSC-EVs onto 200 mesh nickel formvar carbon coated grids 
(Electron Microscopy Science) for 20 min. This was followed by 
fixation in a 2.5% glutaraldehyde/2% sucrose solution. Following 
repeated washings in distilled water, samples were negatively 
stained with NanoVan (Nanoprobes, Yaphank) and examined by 
a Jeol JEM 1010 electron microscope (Joel, USA).
statistical analyses
Data analyses were performed using GraphPad Prism 6.0. Results 
are expressed as mean ± SD or SEM where indicated. Statistical 
analyses were performed by employing: Student’s t-test, one way 
ANOVA, or two-way ANOVA with a multi comparison test 
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where appropriate. A p value of <0.05 was considered statistically 
significant.
resUlTs
hlsc-eVs Prevent Development of cKD
The body weight of mice measured weekly prior to AA 
injection (see in  vivo model schematic, Figure  1A) was 
significantly reduced with respect to controls injected with 
the vehicle alone. The difference in weight was statistically 
significant after the second injection (week 2) and continued 
to remain low until sacrificing at week 4 (Figure 1B). On the 
other hand, body weight of AA mice injected with HLSC-EVs 
increased gradually reaching a significant difference at week 
4 compared to mice treated with AA alone. In contrast, mice 
treated with Fibro-EVs lost more weight compared to mice 
injected with AA only (Figure  1B). Serum creatinine levels 
were significantly increased in AA treated mice at week 4 with 
respect to controls. In contrast, mice treated with HLSC-EVs 
had significantly reduced levels of serum creatinine compared 
to mice treated with AA alone or with Fibro-EV, which served 
as a negative control (Figure 1C). Assessment of morphologi-
cal alterations revealed severe tubular damage in mice injected 
with AA. The major changes included diffuse degeneration of 
the proximal tubular epithelium together with hyaline cast 
formation and tubular necrosis (Figures  2A,D). However, 
mice treated with HLSC-EVs had significantly lower num-
ber of hyaline casts and necrotic tubules compared to mice 
injected with AA alone (Figures 2A,D). The histological score 
obtained by quantifying tubular necrosis in kidney sections 
of every experimental group showed a statistically significant 
increase in AA mice (compared to control mice) and a signifi-
cant reduction (protection) in mice treated with HLSC-EVs 
(compared to AA mice) (Figure 2D). No significant reduction 
in tubular necrosis was observed in mice treated with Fibro-
EVs (Figure 2D).
Kidney fibrosis, as demonstrated by Masson’s trichrome 
staining, showed an increase in tubular damage and interstitial 
fibrosis 4 weeks after AA injection (Figures 2B,E), which was sig-
nificantly reduced by treatment with HLSC-EVs (Figures 2B,E). 
Some reduction of fibrosis was also observed in Fibro-EV treated 
mice. However, the reduction observed was significantly less 
effective compared to HLSC-EV treatment. PCNA (a marker 
of cell proliferation) analysis showed a significant increase in 
PCNA-positive cells in AA animals treated with HLSC-EVs but 
not with Fibro-EVs (Figures 2C,F).
Immunohistochemical staining of kidney cryo-sections 
showed that mice treated with AA had significantly elevated 
numbers of CD45, FSP-1, and α-SMA positive cells as 
well as type 1 collagen deposition compared to controls 
(Figures 3A,B). However, on treating mice with HLSC-EVs, 
expression levels of CD45, FSP-1, α-SMA, and Collagen 1 
were markedly reduced (Figure 3C). Morphometric analyses 
revealed a significant difference between the three experimen-
tal groups of animals, showing a protective effect of HLSC-EVs 
on AA induced injury (Figure  3E). However, no significant 
reduction in the expression levels of CD45, FSP-1, α-SMA, 
and Collagen 1 were observed in mice treated with Fibro-EVs 
(Figures 3D,E).
hlsc-eVs Downregulate Pro-Fibrotic 
genes in Kidneys of aa-Treated Mice
Kidney tissue obtained from mice treated with AA in the 
presence or absence of EVs was subjected to RNA isolation. 
Real-time PCR showed mice treated with AA had significantly 
upregulated levels of the pro-fibrotic genes: alpha smooth muscle 
actin (α-Sma) (Figure 4A), Col1a1 (collagen 1a1) (Figure 4B), 
and Tgfb1 (TGFβ 1) (Figure 4C). Furthermore, we also observed 
an upregulation of the gene latent-transforming growth fac-
tor beta-binding protein 1 (Ltbp1) that codes for the protein 
(LTBP1), which is responsible for activating TGFβ1 from its 
latent form (Figure 4D). In contrast, mice treated with HLSC-
EVs had a significant reduction in the expression levels of all 
three pro-fibrotic genes (Figures 4A–C). In addition, a down-
regulation of Ltbp1 gene was also observed in mice treated with 
HLSC-EVs (Figure 4D). Mice treated with Fibro-EVs showed no 
significant downregulation of pro-fibrotic genes as well as Ltbp1 
(Figures 4A–D).
hlsc-eVs Downregulate Pro-Fibrotic 
genes in Fibroblasts In Vitro
In order to study the effects of HLSC-EVs on renal fibroblasts, 
an in  vitro model was set up whereby mTECs pre-exposed to 
AA were cocultured with fibroblasts in a transwell system. A 
significant rise in α-Sma, Tgfb1, Col1a1 expression levels was 
observed in fibroblasts exposed to mTEC pre-treated with AA 
compared to control (Figures  5A–C). This upregulation of 
pro-fibrotic genes was significantly reduced in the presence of 
HLSC-EVs, but not Fibro-EVs (Figures  5A–C). Furthermore, 
internalisation of HLSC-EVs by mkCF cells (co-incubation for 
6 h) was confirmed by z-stack imagery obtained through confocal 
microscopy (Figure 5D).
Mouse mirnome array
In order to analyse the regulation of miRNAs in kidneys of mice 
treated with AA in the presence or absence of HLSC-EVs, the 
mouse miRNome miRNA profiling kit was adopted. Analyses of 
the data revealed that out of 709 miRNAs analysed, 38 miRNAs 
were upregulated and 92 were downregulated in mice treated 
with AA (Table S1 in Supplementary Material). Furthermore, an 
upregulation of 37 miRNAs and downregulation of 47 miRNAs 
was also observed in AA mice treated with HLSC-EVs (Table S2 
in Supplementary Material).
Comparing the list of miRNAs upregulated in AA mice with 
the list of miRNAs downregulated on treating the mice with 
HLSC-EVs, 8 miRNAs were found to be common (Figure 6A). 
Furthermore, a comparison was also made to identify miRNAs 
that were downregulated by AA and upregulated when treating 
them with HLSC-EVs. The comparison revealed 20 miRNAs to 
be common between the two groups (Figure  6B). Expression 
levels of the 28 miRNAs regulated by HLSC-EVs were verified 
in fibroblasts from the in  vitro system. It was observed that 
out of the 28 miRNAs regulated by HLSC-EVs in  vivo, 5 were 
FigUre 2 | Histological analyses of aristolochic acid nephropathy (AAN) in vivo model. (a) Representative micrographs of H&E-stained renal tissue from healthy 
mice injected with vehicle alone (control), or mice injected with aristolochic acid (AA), or AA mice treated with human liver stem cell-derived extracellular vesicles 
(HLSC-EVs). (B) Representative micrographs of Masson’s trichrome stained renal sections from control, AA, or HLSC-EVs treated AA mice. The blue stain 
represents collagen fibres considered to be a marker for interstitial fibrosis. Original magnification at 400×. (c) Representative micrographs of proliferating cell 
nuclear antigen (PCNA) stained renal tissue of control, AA, or AA mice treated with HLSC-EVs original magnification at 400×. (D) Histological score of tubular 
necrosis in AAN mice experimental groups. Mice treated with AA had significantly elevated levels of tubular necrosis, which was alleviated on treatment with 
HLSC-EVs. No significant reduction in tubular necrosis was observed in mice treated with Fibro-EVs. Data represent mean ± SD of tubular necrosis observed under 
high power field (original magnification: 400×). A one-way analyses of variance (ANOVA) with Bonferroni’s multi comparison test was performed. ***p < 0.001 AA vs 
control or HLSC-EVs vs AA, #p < 0.01 Fibro-EVs vs HLSC-EVs. (e) Histological quantification of interstitial fibrosis in AAN mice experimental groups by multiphase 
image analysis of 10 fields per section. Data represent mean ± SD; a one-way ANOVA with Bonferroni’s multi comparison test was performed. ***p < 0.001 AA vs 
control, **p < 0.01 HLSC-EVs vs AA, #p < 0.01 Fibro-EVs vs HLSC-EVs. (F) Histological score of PCNA positive cells in AAN mice experimental groups observed 
under high power with an original magnification of 400×. An increase in PCNA positive cells (marker for proliferation) was observed in HLSC-EVs treated mice renal 
tissue. No significant increase in PCNA was observed in AA mice treated with Fibro-EVs compared to control. Data represent mean ± SD. A one-way ANOVA with 
Bonferroni’s multi comparison test was performed. **p < 0.01 AA vs control, or Fibro-EVs vs HLSC-EVs, *p < 0.05 HLSC-EVs vs AA, #p < 0.01 Fibro-EVs vs 
HLSC-EVs (n = 9 mice per group).
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downregulated and 2 upregulated in fibroblasts cocultured with 
AA pre-treated mTECs in vitro (Figures 6C,D).
After identifying common miRNAs that inversely correlated 
between mice treated with AA and AA mice treated with HLSC-
EVs, we sought to investigate the genes and pathways that were 
regulated by these miRNAs. Mirwalk analyses identified over 
7,000 predicted genes that were regulated by these miRNAs 
(data not shown). On analysing these genes using Panther gene 
ontology software online, 141 pathways were linked with the 
miRNA targeted genes inputted. These pathways were ranked 
according to the number of genes involved per pathway and 
the top 36 pathways were selected based on the cut off of >5 
FigUre 3 | Immunofluorescent staining of kidneys from mice treated with aristolochic acid (AA). Kidney cryo-sections from healthy mice (a), mice treated with AA 
(B), AA mice treated with HLSC-EVs (c), or Fibro-EVs (D) were stained for collagen 1a1, fibroblast-specific protein 1 (FSP-1), CD45, and α-SMA to identify 
presence of tissue fibrosis, fibroblasts, and inflammatory cells (Original magnification: 200×). (e) Histograms depicts the fluorescence intensity of collagen, FSP-1, 
α-SMA, and quantification of cells positive for CD45 in mouse kidney cryo-sections from AAN mice experimental groups. Data represent mean ± SD of the 
fluorescence intensity or cells positive per high power field measured from 10 images taken at random from six samples per treatment (n = 6 mice). ***p < 0.001 AA 
vs control or HLSC-EVs vs AA. No significant differences were observed between AA vs Fibro-EVs.
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genes/pathway (Table  2). Interestingly, out of the pathways 
identified, quite a few have been implicated in fibrosis including, 
the wingless-related integration site (WNT) signalling pathway, 
inflammatory cytokine and chemokine pathway, platelet derived 
growth factor, fibroblast growth factor (FGF), and TGFβ signal-
ling pathways (Figure 7A; Table 2). Out of interest, the WNT 
signalling pathway had the highest number of the predicted 
miRNA target genes.
FigUre 4 | Human liver stem cell-derived extracellular vesicles (HLSC-EVs) downregulate pro-fibrotic genes in mice treated with aristolochic acid (AA). Gene 
expression levels of α-Sma (a), Col1a1 (B), Tgfb1 (c), and Ltbp1 (D) in mice treated with vehicle alone (control), mice treated with AA, AA mice treated with 
HLSC-EVs or Fibro-EVs. Data show mean ± SD of n = 7 mice per treatment. ***p < 0.001 AA vs control, *p < 0.05, **p < 0.01, ***p < 0.001 HLSC-EVs vs AA.  
No significant differences were observed between AA vs Fibro-EVs.
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In order to understand the regulation of genes involved in 
fibrosis in the current AAN model, mice treated with AA in 
the presence or absence of HLSC-EVs were analysed through a 
Fibrosis RT2 Profiler PCR array (Qiagen). Out of 84 genes in the 
array, 35 were found to be upregulated in mice treated with AA and 
14 genes downregulated in HLSC-EV treated mice (Figure 7B; 
Table 3). On comparing the genes between the two experimental 
groups, five genes were found to be common (upregulated in 
AA treated mice and downregulated in HLSC-EV treated mice) 
(Figure 7B; Table 3). Altogether, these results suggest that HLSC-
EVs could mediate the progression and development of fibrotic 
events through the regulation of miRNAs and pro-fibrotic genes.
DiscUssiOn
In the current study, we demonstrate that HLSC-EVs prevent the 
development of interstitial fibrosis and tubular necrosis, favours 
renal regeneration, and reduces the infiltration of inflammatory 
immune cells in a CKD mouse model of AAN. Furthermore, 
there is also an improvement in kidney function as observed 
through significantly low levels of plasma creatinine.
The beneficial effects of bone marrow MSC-derived EVs on 
AKI was first reported by Bruno et al. (12). They showed that a 
single intravenous dose of MSC-EVs at the peak of the damage was 
sufficient to alleviate morphological and functional impairment 
in a glycerol induced model of AKI (12). Thereafter, several stud-
ies have reported the beneficial effects of stem cell-derived EVs in 
various models of AKI. For instance, in a lethal model of cisplatin 
induced AKI, the authors observed that a single intravenous dose 
of MSC-EVs improved renal function and morphology, therefore, 
improving overall survival rate of injured mice (23). In addition, 
this effect was further enhanced by the administration of multiple 
doses of MSC-EVs (23). In another study, human umbilical cord 
blood derived MSC-EVs injected through the caudal vein reduced 
damage in a cisplatin-induced AKI model in vivo and in vitro (24). 
A similar regenerative and therapeutic effect was also observed 
by Burger et al. (25) in their model of AKI, whereby EVs from 
endothelial precursor cells were injected through the jugular vein 
(25). There is, therefore, sufficient evidence to show that MSC 
derived EVs exhibit therapeutic effects in various models of AKI 
regardless the source or route of administration. Although, plenty 
of research has been published over the years on stem cell derived 
EVs in AKI, very few studies can be found reporting the effect of 
EVs in CKD (23, 26). Nonetheless, these studies have shown that 
MSC derived EVs may prevent CKD progression (13, 26–29). 
For instance, in a rat model of ischemia–reperfusion-induced 
(IRI) chronic kidney injury, Gatti et al. showed that MSC-EVs, 
not only improved kidney function by reducing elevated levels 
of blood urea nitrogen and creatinine, but also prevented further 
progression to fibrosis (13). Furthermore, a subsequent study in 
a similar model of IRI reported a reduction in the infiltration of 
inflammatory cells mainly through the suppression of fractalkine 
(CX3CL1) mediated by MSC-EVs (30). Apart from single doses 
of EVs, multiple doses have also proven to be effective in CKD. 
FigUre 5 | Human liver stem cell-derived extracellular vesicles (HLSC-EVs) downregulate pro-fibrotic genes in mkCF in an in vitro model of aristolochic acid 
nephropathy. mTECs pre-treated with 100 µM aristolochic acid (AA) for 4 h were cocultured with mouse fibroblasts in the presence or absence of HLSC-EVs or 
Fibro-EVs (50,000 EVs/cell) for 5 days at 37°C. Post experimental analyses revealed an upregulation of the fibrotic markers: (a) α-sma, (B) Tgfb1, and (c) Col1a1 in 
mkCF cocultured with AA-treated mTECs (AA). Treatment with HLSC-EVs, but not Fibro-EVs, significantly downregulated all three genes compared to control. The 
data represent mean ± SEM of three independent experiments performed in quadruplicate. *p < 0.05, **p < 0.01, ***p < 0.001 mTEC + AA vs Control, or 
HLSC-EVs vs mTEC + AA. No significant differences were observed between mTEC + AA vs Fibro-EVs. A one-way analyses of variance with Bonferroni’s multi 
comparison test was performed. (D) Representative confocal microscopy depicting the uptake of 1 × 1010 Dil dye-labelled HLSC-EVs by mkCF after 6 h of 
co-incubation at 37°C. Z stack analyses shows the presence of EVs within the cytoplasm (phalloidin staining, green) of the cells indicating an effective internalisation 
of vesicles (in red); scale bar = 50 μm. Data represent one of the three experiments performed with similar results.
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For example, several injections of urine derived stem cell EVs not 
only prevented apoptosis of podocytes and tubular epithelial cells, 
but also favoured proliferation of glomerular endothelial cells, 
therefore, exhibiting an overall regenerative effect in a model of 
Type 1 diabetes (31). Although, in the past, we have reported how 
HLSC-EVs promote regeneration and recovery in AKI (9), no 
studies have been performed investigating the biological activity 
of HLSC-EVs in CKD. Here, we report for the first time the effect 
of HLSC-EVs in a severe AAN model of CKD in NSG mice.
One of the key features of CKD is loss of kidney function 
reflected by the rise in blood creatinine levels as observed in vari-
ous models of CKD including AAN (2, 13, 28, 32). The findings 
of the current study are in line with these reports as mice treated 
with AA had significantly elevated levels of creatinine. We also 
observed that treatment with HLSC-EVs was able to reduce blood 
creatinine in injured mice significantly, therefore, confirming 
the ability of HLSC-EVs to improve renal function as observed 
previously in our model of AKI (9). Another key factor in the 
progression of CKD is interstitial inflammation characterised by 
infiltrating immune and inflammatory cells regardless the cause of 
injury (5). Depierreux for instance reported the presence of lym-
phocytic infiltration in biopsies of patients with AAN (33). Later 
on, Pozdzik et al. (34, 35) confirmed this in human patients with 
AAN as well as in a rat AAN model whereby an influx of activated 
mononuclear cells and cytotoxic T lymphocytes was observed in 
the renal interstitium (34, 35). A similar finding was also obtained 
in another study, whereby the authors reported infiltration of 
CD45 positive immune cells in their mouse model of AAN (36). 
In the present study, an infiltration of CD45-positive cells was 
also observed 30 days after initiating the damage with AA. We, 
therefore, speculate that, these cells are likely to be monocytes 
and neutrophils as NSG mice lack lymphocytes and natural killer 
cells and have macrophages and dendritic cells, which are defec-
tive due to their genetic background (37). Interestingly, AA mice 
FigUre 6 | Venn diagram comparing microRNAs (miRNAs) regulated by HLSC-EVs treatment in vivo and in vitro. (a) 38 miRNAs were upregulated in mice treated 
with aristolochic acid (AA) and 47 miRNAs were downregulated in AA mice treated with human liver stem cell-derived extracellular vesicles (HLSC-EVs). Eight 
miRNAs were common between the two groups. (B) 92 miRNAs were downregulated in mice treated with AA and 37 were upregulated on treating the AA mice with 
HLSC-EVs. Twenty miRNAs were common between the two groups. n = 3 mice/treatment. Expression levels of miRNAs regulated by HLSC-EVs in vivo were 
verified in mkCF cocultured with AA pre-treated mTECs. Five were found to be downregulated in vitro (c), and two miRNAs upregulated (D). The data represent 
mean ± SEM of three independent experiments performed in quadruplicate.
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treated with HLSC-EVs had lower counts of CD45 mononuclear 
cells, therefore, suggesting an immune/anti-inflammatory role of 
these HLSC-EVs not been reported previously in CKD.
Another key feature of CKD is tubular damage and hyaline cast 
formation, which has also been characterised in various models of 
AAN (36, 38, 39). The development of proximal tubular necrosis 
and cast formation was recapitulated in this model representing 
the predominant lesions observed. Interestingly, treatment with 
HLSC-EVs significantly reduced tubular necrosis in our model 
compared to treatment with vehicle alone. In addition, a marked 
TaBle 2 | Panther pathway enrichment analyses.
Pathways predicted by PanTher online  
meta-analyses
no of genes 
involved
Wnt signalling pathway (P00057) 104




Cadherin signalling pathway (P00012) 57
Integrin signalling pathway (P00034) 53
Platelet-derived growth factor signalling pathway (P00047) 52
epidermal growth factor receptor signalling pathway (P00018) 43
Fibroblast growth factor signalling pathway (P00021) 40
apoptosis signalling pathway (P00006) 38
Ras Pathway (P04393) 34
endothelin signalling pathway (P00019) 31
T cell activation (P00053) 31
interleukin signalling pathway (P00036) 30
Cytoskeletal regulation by Rho GTPase (P00016) 27
p53 pathway (P00059) 27
TgF-beta signalling pathway (P00052) 27
VegF signalling pathway (P00056) 23
B cell activation (P00010) 21
Oxidative stress response (P00046) 19
p38 MAPK pathway (P05918) 18
Beta1 adrenergic receptor signalling pathway (P04377) 17
Beta2 adrenergic receptor signalling pathway (P04378) 17
PI3 kinase pathway (P00048) 17
Toll receptor signalling pathway (P00054) 17
Dopamine receptor mediated signalling pathway (P05912) 15
Insulin/IGF pathway-protein kinase B signalling cascade (P00033) 13
Hypoxia response via HIF activation (P00030) 12
FAS signalling pathway (P00020) 11
Histamine H1 receptor mediated signalling pathway (P04385) 11
Interferon-gamma signalling pathway (P00035) 11
Transcription regulation by bZIP transcription factor (P00055) 11
Angiotensin II-stimulated signalling through G proteins and beta-
arrestin (P05911)
10
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP 
kinase cascade (P00032)
10
Histamine H2 receptor mediated signalling pathway (P04386) 9
notch signalling pathway (P00045) 9
JaK/sTaT signalling pathway (P00038) 6
Pathways regulated by microRNAs downregulated by human liver stem cell-derived 
extracellular vesicles in aristolochic acid mice. Out of 141 pathways identified, 36 
pathways have been selected on the basis of number of genes involved.
Bold red indicated  the pathways and gene numbers implicated in kidney fibrosis.
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increase in proliferating cells confirmed by PCNA staining in 
HLSC-EV-treated mice kidneys demonstrate regeneration and 
recovery of damaged renal tissue. Indeed, these tissue healing 
properties of stem cell-derived EVs and HLSC-EVs, in particular, 
have been reported in an AKI model previously (9). However, the 
observation of similar effects extended to CKD is novel.
Irrespective to the cause of injury, interstitial fibrosis is the 
final common process that defines CKD and is characterised by 
proliferation of resident fibroblasts and progressive accumulation 
of ECM primarily collagen (5, 36). In this study, we observed an 
increase in the infiltration/proliferation of fibroblasts in the renal 
interstitium, which correlated with an increase in Collagen type 
1 level in mice treated with AA. These findings were consistent 
with what has been reported in other models of AAN (34–36, 40), 
in particular, by Huang et al. (36) who also reported an increase 
of FSP-1 positive cells in a mouse model of chronic AAN. 
Moreover, AA mice treated with HLSC-EVs had a significantly 
reduced percentage of fibroblasts, as well as collagen deposition 
in the renal interstitium. A similar result was also observed at 
a molecular level whereby, expression levels of the pro-fibrotic 
genes α-Sma, Col1a1, and Tgfb1 were downregulated in mice 
renal tissue treated with HLSC-EVs. This result was supported 
by in vitro data whereby HLSC-EVs downregulated pro-fibrotic 
genes mentioned above, in renal cortical fibroblasts cocultured 
with AA exposed mTECs. This finding, therefore, suggests a 
novel role of HLSC-EVs as mediators of fibroblast activation.
TGFβ is considered to be a major driver of ECM synthesis, 
inhibition of ECM degradation and activation of myofibroblasts, 
all of which lead to the development of fibrosis (5). Furthermore, 
the upregulation of this cytokine has been reported in various mod-
els of AAN (34, 40–42). We, therefore, investigated the molecular 
events involved around the TGFβ signalling pathway that lead to 
the development of fibrosis, and whether, the healing properties of 
HLSC-EVs observed in the current model could be due to the regu-
lation of the genes governed by this pathway. Thirty genes related 
to fibrosis were identified to be upregulated in mice treated with 
AA. Some of these genes such as: Cav1, Dcn, Grem1, Ltbp1, Tgfb1, 
etc., belong to the TGFβ superfamily including two genes (Jun and 
Myc) that code for transcription factors involved in the pathway. On 
the other hand, 14 pro-fibrotic genes in total were downregulated in 
mice treated with HLSC-EVs, five of which were initially upregulated 
in AA mice (Table 2). These 14 genes regulate various pathways that 
are dysregulated during fibrosis including: cytokine and chemokine 
pathways, growth factors, regulation of the ECM, etc.
Out of the five pro-fibrotic genes downregulated by HLSC-EV 
treatment, Ccr2 and Ccl12 code for inflammatory chemokines, 
which have a receptor–ligand relationship (43). Furthermore, 
they have also been implicated in fibrosis. For instance, Moore 
et al. (43) in their study showed that mice genetically deficient in 
Ccr2 gene were protected from lung fibrosis. Furthermore, neu-
tralisation of Ccl12 in wild-type mice significantly protected them 
from FITC-induced lung fibrosis by preventing the recruitment of 
fibrocytes (43). Similarly, in another study, the blocking of Ccr2, 
either through gene silencing or inhibitors reduced renal intersti-
tial fibrosis induced by unilateral ureter obstruction in mice (44). 
Furthermore, this blockade of Ccr2 resulted in the downregulation 
of TGFβ, and type 1 collagen both at a molecular and protein level 
(44) as was observed in our model. Another gene that was down-
regulated through the treatment of HLSC-EVs was snail family 
zinc finger 1 (Snai1). This gene codes for the transcription factor 
SNAI1 that is very well known to mediate biological processes 
involved in renal fibrogenesis including EMT of tubular epithelial 
cells, cell cycle arrest, and inflammation (45). Furthermore, it 
has also been reported to be upregulated in the kidney tissue of 
patients with various types of progressive nephropathy (46).
Latent-transforming growth factor beta-binding protein 
1 (LTBP1) is a gene that codes for the LTBP1 protein. TGFβ is 
normally secreted as a latent form comprised of three compo-
nents: the mature TGFβ dimer, the latency-associated peptide, 
and LTBP (47). LTBP1 not only facilitates the formation and 
release of latent TGFβ but is also involved in the activation of 
the cytokine. Furthermore, both TGFβ and LTBP1 were found 
to be upregulated in patients with idiopathic lung fibrosis (48). 
FigUre 7 | Panther pathway analyses of microRNAs (miRNAs) regulated by human liver stem cell-derived extracellular vesicles (HLSC-EVs) and Venn diagram 
illustrating the pro-fibrotic genes. (a) Pie chart showing various pathways involved in the process of aristolochic acid (AA) kidney injury as described in Table 2. 
Pathway analyses of miRNAs regulated by HLSC-EVs in AA mice showed the regulation of wingless-related integration site signalling pathway, platelet derived 
growth factor signalling pathway, fibroblast growth factor, and TGFβ signalling pathway. (B) Venn diagram of pro-fibrotic genes regulated in mice treated with AA and 
in AA mice treated with HLSC-EVs showed 35 genes were upregulated in mice treated with AA and 14 genes were downregulated in AA mice treated with 
HLSC-EVs out of which 5 genes were upregulated by AA.
13
Kholia et al. EVs Inhibition of Kidney Fibrosis
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1639
TaBle 3 | Regulation of pro-fibrotic genes in AA mice and AA mice treated with 
HLSC-EVs.




















Thirty five genes were upregulated in mice treated with aristolochic acid (AA). Fourteen 
genes were downregulated in AA mice treated with human liver stem cell-derived 
extracellular vesicles (HLSC-EVs). Five genes were common between the two lists 
(highlighted in red).
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Consistent with this report, we also observed an upregulation of 
Ltbp1 expression levels together with Tgfb1 in mice renal tissue 
exposed to AA. However, interestingly, mice treated with HLSC-
EVs showed lower expression levels of both genes. As mentioned 
previously, as LTBP1 is important for the activation of TGFβ, 
this finding could provide one explanation of the mechanism of 
action of HLSC-EV mediated downregulation of TGFβ1.
MicroRNAs are small, non-coding RNAs that regulate gene 
expression by suppressing or degrading target mRNA at a post-
transcriptional level (49). They have been implicated in various 
physiological and pathological processes including fibrosis (49). 
We, therefore, investigated the regulation of miRNAs in mice 
injured with AA and AA mice treated with HLSC-EVs. After 
identifying the common miRNAs that were inversely correlated 
between AA mice and mice treated with HLSC-EV, we analysed 
the genes and pathways that were regulated by these miRNAs. 
Inputting the data into bioinformatic analyses databases online, we 
identified over 7,000 genes that were regulated by these miRNAs 
(data not shown). Furthermore, Panther pathway analyses linked 
these genes to 141 pathways out of which the top 36 pathways 
(ranked according to the number of genes involved per pathway; 
Table 2) have been reported here. Out of the pathways identified, 
quite a few have been implicated in fibrosis such as the WNT 
signalling pathway (50), inflammatory cytokine, and chemokine 
pathways (51), as well as PDGF, FGF, and TGFβ pathways (52).
Taken together, we demonstrate for the first time the healing 
properties of HLSC-EVs in a model of CKD. Our data indicate 
that multiple injections of HLSC-EVs exhibit a regenerative, 
anti-fibrotic, and anti-inflammatory role in a mouse model of 
AAN characterised by severe tubular epithelial cell necrosis and 
interstitial fibrosis. Furthermore, downregulation of pro-fibrotic 
genes and modulation of miRNAs that regulate the fibrotic path-
ways could be a mechanism through which HLSC-EVs exert their 
biological activity. These findings may promote the development 
of new therapeutic strategies involving HLSC-EVs in CKD.
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